Item 2.02 Results of Operations and Financial Condition. On January 4, 2022, Moderna, Inc. (the "Company") issued a letter to its shareholders, which included the Company's current expectations with respect to its cash, cash equivalents, and investments in marketable securities as of December 31, 2021 and the number of doses of its COVID-19 vaccine delivered during the year ended December 31, 2021. A copy of the letter is attached hereto as Exhibit 99.1. Item 7.01 Regulation FD Disclosure.

On January 4, 2022, the Company issued a letter to its shareholders. A copy of the letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in Items 2.02 and 7.01 (including Exhibit 99.1) to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit
     No.             Description
    99.1               Letter dated January 4, 2022, from Moderna, Inc. to its shareholders
     104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses